RUNX2 regulates the effects of TNFalpha on proliferation and apoptosis in SaOs-2 cells
- PMID: 20053387
- DOI: 10.1016/j.bone.2009.12.027
RUNX2 regulates the effects of TNFalpha on proliferation and apoptosis in SaOs-2 cells
Abstract
The runt-related transcriptional factor RUNX2 is an essential mediator of the osteoblast phenotype and plays a pivotal role in the process of osteoblast differentiation. The involvement of RUNX2 includes the regulation of genes that are important in committing cells to the osteoblast lineage. Increasing evidences are consistent with a requirement of RUNX2 for stringent control of osteoblast proliferation and recent data even suggested that RUNX2 might act as a proapoptotic factor. Among the cytokines described as modulators of osteoblast functions, TNFalpha affects both apoptosis and the differentiation rate from mesenchymal precursor cells of osteoblast. Thus we evaluated on the human osteosarcoma cell line SaOs-2 stably transfected with a RUNX2 dominant negative construct (DeltaRUNX2) the effects of serum and TNFalpha on proliferation and apoptosis. In this study we showed that SaOs-2 clones expressing high levels of DeltaRUNX2 presented a higher proliferation rate than clones transfected with an empty vector. This increase in cell growth was accompanied by a rise in cyclins A1, B1 and E1 expression and a decrease in the cyclin inhibitor p21. Moreover we observed that the expression of the RUNX2 transgene protected the SaOs-2 cells from the antiproliferative and the apoptotic effects induced by TNFalpha. This was accompanied by the inhibition of Bax and activation of Bcl2 expression. Experiments done on SaOs-2 cells transiently transfected with siRNA confirmed that RUNX2 represents a critical link between cell fate, proliferation and growth control. This study also suggested that RUNX2 might control osteoblastic growth depending on the differentiation stage of the cells by regulating expression of elements involved in hormones and cytokines sensitivity.
Copyright 2009 Elsevier Inc. All rights reserved.
Similar articles
-
TNF-alpha's effects on proliferation and apoptosis in human mesenchymal stem cells depend on RUNX2 expression.J Bone Miner Res. 2010 Jul;25(7):1616-26. doi: 10.1002/jbmr.52. J Bone Miner Res. 2010. PMID: 20200969
-
Effects of Cissus quadrangularis on the proliferation, differentiation and matrix mineralization of human osteoblast like SaOS-2 cells.J Cell Biochem. 2011 Apr;112(4):1035-45. doi: 10.1002/jcb.23016. J Cell Biochem. 2011. PMID: 21308732
-
Fidgetin-like 1 gene inhibited by basic fibroblast growth factor regulates the proliferation and differentiation of osteoblasts.J Bone Miner Res. 2007 Jun;22(6):889-96. doi: 10.1359/jbmr.070311. J Bone Miner Res. 2007. PMID: 17352653
-
Regulation of bone development and extracellular matrix protein genes by RUNX2.Cell Tissue Res. 2010 Jan;339(1):189-95. doi: 10.1007/s00441-009-0832-8. Epub 2009 Aug 1. Cell Tissue Res. 2010. PMID: 19649655 Review.
-
Regulation of Proliferation, Differentiation and Functions of Osteoblasts by Runx2.Int J Mol Sci. 2019 Apr 4;20(7):1694. doi: 10.3390/ijms20071694. Int J Mol Sci. 2019. PMID: 30987410 Free PMC article. Review.
Cited by
-
Sodium butyrate has anti-proliferative, pro-differentiating, and immunomodulatory effects in osteosarcoma cells and counteracts the TNFα-induced low-grade inflammation.Int J Immunopathol Pharmacol. 2018 Jan-Dec;32:394632017752240. doi: 10.1177/0394632017752240. Int J Immunopathol Pharmacol. 2018. PMID: 29363375 Free PMC article.
-
Lower limb arterial calcification and its clinical relevance with peripheral arterial disease.Front Cardiovasc Med. 2023 Nov 24;10:1271100. doi: 10.3389/fcvm.2023.1271100. eCollection 2023. Front Cardiovasc Med. 2023. PMID: 38075978 Free PMC article. Review.
-
Loss of Runx2 sensitises osteosarcoma to chemotherapy-induced apoptosis.Br J Cancer. 2015 Nov 3;113(9):1289-97. doi: 10.1038/bjc.2015.305. Epub 2015 Oct 15. Br J Cancer. 2015. PMID: 26528706 Free PMC article.
-
Inflammatory, Metabolic, and Coagulation Effects on Medial Arterial Calcification in Patients with Peripheral Arterial Disease.Int J Mol Sci. 2023 Feb 5;24(4):3132. doi: 10.3390/ijms24043132. Int J Mol Sci. 2023. PMID: 36834544 Free PMC article. Review.
-
Bone anabolic agents for the treatment of multiple myeloma.Cancer Microenviron. 2011 Dec;4(3):339-49. doi: 10.1007/s12307-011-0090-7. Epub 2011 Dec 3. Cancer Microenviron. 2011. PMID: 22139744 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials